Mahana App Review: An Honest Take from a Hypnotherapist Who Treats IBS

The short version. Mahana is a real evidence-based intervention for IBS. It is FDA-cleared as a digital therapeutic in the United States, it delivers a structured 90-day CBT-for-IBS program adapted from in-person protocols, and the underlying mechanism has solid research behind it. It is also not the strongest individual treatment available for IBS. For some clients it is exactly the right starting point. For others it is the wrong tool, and pretending otherwise leaves people stuck.

The honest framing

Most app reviews fall into one of two failure modes. Either they read like marketing, where every feature is a breakthrough and every user is delighted. Or they read like a competitive takedown, where the reviewer wants you to book their service instead and so the app can do nothing right. This is neither. I work with IBS clients in my hypnotherapy practice, and I am writing a review of an app that competes with my service in some cases and is the right tool in others. Treating that honestly is the point.

Mahana is one of the few mental-health digital therapeutics with specific regulatory approval for a defined condition. In the United States it has FDA clearance as a prescription digital therapeutic for IBS. That is meaningful. The path to FDA clearance for a software product requires the company to put forward outcome evidence under regulatory scrutiny, and most apps in the wellness category have not done that. Mahana sitting in a different regulatory category from the average meditation app is real, and anyone considering the app should know it.

The product itself is a structured 90-day CBT-for-IBS program. Daily lessons, cognitive and behavioural exercises, symptom tracking, and between-day prompts. The content is adapted from in-person CBT-for-IBS protocols that have a long research history. This is not a generic wellness app dressed up as a therapy product. It is structured CBT for IBS in app form, which is a meaningful distinction.

Where Mahana fits well. A structured first-line option for clients with confirmed IBS who want a self-guided digital path before committing to individual hypnotherapy or in-person CBT. A reasonable step in the sequence when cost or access to in-person care is a real barrier. A useful psychological layer alongside primary gastroenterology and dietary care.

Where Mahana does not fit. Severe IBS with significant functional impairment. Treatment-refractory cases that have already failed other psychological work. Clients with active comorbid severe anxiety, depression, or trauma where the app structure cannot adapt to individual circumstances. Clients who realistically cannot maintain 90 days of self-directed daily app use. Active eating disorders presenting with GI symptoms. Pre-diagnostic GI symptoms not yet medically evaluated.

One disclosure worth making explicit. As a Registered Clinical Hypnotherapist working within a defined scope of practice, I do not diagnose IBS, I do not prescribe medication, and I do not replace your gastroenterologist. Clients arrive in my practice with a confirmed IBS diagnosis from their GP or GI specialist. What I provide is gut-directed hypnotherapy as complementary care, following the Manchester Protocol. The same scope rules apply when I evaluate any other product in this category, including Mahana. I am reviewing the app as one option in a landscape of options, not as a replacement for medical care. For more on what hypnotherapy can and cannot do, see the broader app vs in-person comparison hub where this review fits.

What Mahana actually delivers

Strip away the marketing and the regulatory framing for a moment and look at the product as a user would experience it. A 90-day program, mostly delivered through a smartphone app, with a daily cadence of around 10 to 15 minutes of structured content plus some between-day touchpoints. The arc of the program follows a CBT-for-IBS protocol that has been adapted from in-person delivery formats. Cognitive layer first, then behavioural, with ongoing tracking that runs across the whole 90 days.

The cognitive content focuses on the relationship between thoughts about the gut, anxiety about symptoms, and the actual physiological response in the gut itself. The classic CBT pattern is helping the user notice catastrophic interpretations of normal sensations, build alternative ways of relating to those sensations, and break the loop where worry about symptoms amplifies the symptoms themselves. CBT-for-IBS is more specific than generic CBT because the cognitive content is built around gut-related thinking patterns rather than general anxiety patterns.

The behavioural content is mostly exposure-based homework around feared situations. For an IBS sufferer that often means situations where access to a bathroom is restricted, meals at unfamiliar places, social events where the anticipatory worry compounds, work meetings where leaving is hard. The classic behavioural pattern is gradual approach with structured planning, rather than avoidance that reinforces the anxiety loop. Relaxation training also lives in this layer, often delivered as guided audio content the user listens to as part of daily practice.

Tracking runs the length of the program. The user logs symptom severity, identifies likely triggers, and over time the app surfaces patterns that the user might not otherwise notice. This is a real benefit of structured digital tracking compared to a paper journal that gets abandoned in week two. Done consistently, the tracking data turns into a usable map of the personal IBS pattern, which is information the user can take into gastroenterology appointments or any future psychological work.

Delivery is smartphone-first, mostly self-directed, no live practitioner in the standard offering. That is the core trade. The app is delivering a structured therapy program at a fraction of the cost of in-person CBT-for-IBS, and the way it makes that economics work is by removing the live practitioner from the loop. The content is fixed. The progression is fixed. The user does the work or does not, and the app does not adapt if the user is struggling in a way the program did not anticipate.

Cost varies by access route. In some jurisdictions the app requires a prescription to access. In others it comes through employer-provided digital health benefits. In others it is direct pay. Pricing in 2026 lands in a range that is dramatically lower than 12 weekly sessions of in-person CBT-for-IBS but is not free. For Canadian users, access pathways are still evolving and the practical answer for most clients today is direct pay or employer benefits if available. As a hypnotherapy practice, our standard fee for the gut-directed pathway is $220 per session with a 3-session initial commitment, so the cost comparison depends on how many app months you would use and how many in-person sessions you would otherwise book.

Honest framing on what Mahana is not. It is not generic meditation content. It is not a wellness library. It is not a chatbot that responds to your specific situation. It is structured CBT-for-IBS in app form, which is its own category and should be evaluated as such.

What the evidence shows

The evidence picture for Mahana sits on two layers. The app itself has supportive RCT data for IBS symptom improvement, generated through the regulatory pathway that produced the FDA clearance. The underlying CBT-for-IBS protocol that Mahana adapts has a substantial in-person evidence base going back decades. Both layers matter, and they tell a slightly different story when you look at them carefully.

On the protocol layer, CBT-for-IBS is a well-established psychological treatment with multiple randomized trials supporting symptom improvement, quality-of-life gains, and reductions in healthcare utilization. The effect sizes in the in-person delivery format are real, statistically significant, and clinically meaningful for many patients. When CBT-for-IBS is delivered by a trained therapist in person across 8 to 12 sessions, the per-client benefit is solid evidence-based care for IBS.

On the app layer, Mahana has demonstrated meaningful improvement in IBS symptoms in the trials that supported the regulatory clearance. The effects are real and statistically significant. They are also more modest in magnitude than the strongest individual-treatment evidence in the IBS literature. This is not a knock on Mahana. It is the structural reality of any digital adaptation of a therapy protocol. The app delivery loses some of the personalization, troubleshooting, and therapeutic relationship that in-person care provides, and the effect sizes typically reflect that loss.

The most useful comparator in the IBS psychological-care literature is gut-directed hypnotherapy on the Manchester Protocol. Miller 2015 (PMID 25736234) reported that 76% of refractory IBS patients responded to gut-directed hypnotherapy in an unselected sample of 1,000 consecutive patients, with response defined as at least 50% improvement on validated symptom scoring. That is a large-scale clinic outcome, not an RCT, but it is the strongest single benchmark in the per-client effect-size conversation.

Peters 2016 (PMID 27397586) directly compared gut-directed hypnotherapy to a low-FODMAP diet in a randomized trial of IBS patients and found equivalent symptom relief at 6-month follow-up, with no statistically significant difference between arms. That study positions gut-directed hypnotherapy alongside the most established dietary intervention in IBS care. It does not directly compare gut-directed hypnotherapy to Mahana, and there is no head-to-head trial of the two. The comparison has to be inferred from the relative effect sizes in their own separate trial bases, with all the caveats that implies.

The population that benefits most from Mahana on the evidence: mild-to-moderate IBS, motivated patients who can sustain 90 days of daily app engagement, no severe comorbidity, no prior failure of psychological interventions. The population that benefits less: severe IBS, treatment-refractory presentations, comorbid severe anxiety or depression, patients who structurally struggle with self-directed daily routines.

Compared to in-person CBT-for-IBS, the app delivery is more accessible and lower cost but is typically less effective per-client than in-person individual therapy. That is the structural pattern across most digital therapeutic comparisons in psychological care. The trade-off is a real benefit on access and cost paid for with a smaller per-client effect size. Whether the trade-off is the right one for a specific patient depends entirely on their situation. Per the scope-of-practice frame I work to as a Registered Clinical Hypnotherapist, my role is helping clients think through that trade-off honestly, not pushing them toward whichever option happens to be the one I deliver.

Where Mahana fits in the IBS treatment landscape

The IBS treatment landscape has more options than most patients realize when they first show up at their GP with symptoms. A fair review of any single product, including Mahana, has to place it inside the broader field rather than treating it as if it were the only option. Five layers usually matter.

Medical and gastroenterology care comes first. Confirmed IBS diagnosis, ruling out alarm features, considering targeted medication for specific symptom subtypes (anti-spasmodics, low-dose neuromodulators, IBS-D-specific or IBS-C-specific agents). This is the foundation. Nothing on the psychological side substitutes for it. As a Registered Clinical Hypnotherapist, my clients arrive with a confirmed diagnosis from their GP or GI specialist, never the other way around.

Dietary management is the second layer for many patients. A structured low-FODMAP elimination with a registered dietitian, with planned reintroduction phases, is a first-line evidence-based approach for IBS. Peters 2016 (PMID 27397586) showed that low-FODMAP and gut-directed hypnotherapy produced equivalent symptom relief in their head-to-head trial, which positions diet alongside the strongest psychological options. For patients whose symptoms are heavily food-triggered, dietary work often runs first or in parallel.

The Mahana layer sits in the psychological-care tier as a structured digital therapeutic. It is reasonable as a first-line psychological option for many patients, especially when in-person individual therapy access or cost is a barrier. The 90-day structure is rigorous enough that it is not just a wellness layer. It is real CBT-for-IBS delivered through a digital format, with supportive RCT evidence and FDA clearance behind it.

In-person individual CBT-for-IBS is the higher-evidence version of what Mahana is delivering. A trained therapist across 8 to 12 sessions, fully personalized to the patient, with troubleshooting in real time. Per-client effect size is typically larger than the app version. The cost and access trade-off is the obvious downside, and for many patients in-person individual care is not practical for reasons that have nothing to do with the evidence.

Gut-directed hypnotherapy is the other strong individual psychological option. Manchester Protocol, 8 to 12 sessions across 8 to 12 weeks, with the strongest single benchmark in the IBS psychological-care literature being Miller 2015 (PMID 25736234) reporting 76% response in 1,000 consecutive refractory patients. Peters 2016 (PMID 27397586) showed equivalent symptom relief versus low-FODMAP diet in a head-to-head RCT. The mechanism is different from CBT-for-IBS. Both belong in the conversation.

Pharmacological options sit alongside the psychological tier rather than in competition with it. For some patients medication is part of the picture and runs concurrently with whatever psychological work is being done. For others, the psychological layer is enough on its own. That decision sits with the GI specialist and the patient, not the hypnotherapist or the app.

Where Mahana fits practically. A reasonable first-line psychological option for clients who prefer digital-first care, have budget or access barriers to in-person individual therapy, are willing to commit to 90 days of structured daily app use, and have mild-to-moderate IBS without severe comorbidity. A useful adjunct for clients already in gastroenterology or dietary care who want to add a psychological layer. A reasonable step in the sequence with the option to step up to in-person work if the app does not produce sufficient improvement at 90 days.

Mahana vs gut-directed hypnotherapy (the practitioner take)

This is the comparison most readers want me to be honest about, and it is the one most likely to make a less careful reviewer uncomfortable. I work with IBS clients using gut-directed hypnotherapy on the Manchester Protocol. Mahana delivers a different psychological mechanism (CBT) in a different format (digital therapeutic). Both are legitimate evidence-based options for IBS. They are not the same product, and they fit different best-fit populations.

On per-client effect size in head-to-head context, gut-directed hypnotherapy has the stronger evidence anchor. Miller 2015 (PMID 25736234) reported 76% response in 1,000 consecutive refractory IBS patients on the Manchester Protocol. Peters 2016 (PMID 27397586) showed gut-directed hypnotherapy producing equivalent symptom relief to a low-FODMAP diet at 6-month follow-up in a randomized trial of IBS patients, with no statistically significant difference between arms. Those are the two strongest per-client effect-size benchmarks in the IBS psychological-care literature, and the CBT-for-IBS app delivery does not match those numbers head-to-head, particularly for refractory presentations.

On breadth of psychological coverage, Mahana has the broader surface. CBT-for-IBS works on the cognitive layer (catastrophic interpretations, anxiety about symptoms), the behavioural layer (avoidance, exposure homework), and the somatic layer (relaxation training). Gut-directed hypnotherapy is more narrowly focused on the gut-brain loop specifically, using focused-attention plus targeted suggestion to recalibrate visceral hypersensitivity and the autonomic-nervous-system contribution to IBS symptoms. The narrower focus is part of why it produces strong per-client effects on the gut symptoms themselves. The broader CBT surface is part of why Mahana also reaches anxiety and avoidance patterns that pure gut-directed work touches less directly.

On cost, Mahana is the lower-cost option for most users. A 90-day digital therapeutic program comes in well below the cost of 8 to 12 weekly sessions of in-person individual hypnotherapy. Per the canonical service description for gut-directed hypnotherapy in the practice, sessions are $220 CAD with a standard 3-session initial commitment of $660 CAD, and continuation beyond the initial 3 sessions is optional. A full Manchester Protocol course typically runs 8 to 12 sessions, so the cost difference is real.

On time to effect, the two are comparable. Mahana is a 90-day program. Gut-directed hypnotherapy on the Manchester Protocol is typically 8 to 12 weekly sessions across roughly the same timeframe. Neither is fast. Both require commitment to a structured course of work. A patient who is unwilling to commit 8 to 12 weeks to either format will struggle to extract the full benefit of either.

On clinical positioning. For clients ready for individual care, with the resources, and with a presentation in the moderate-to-severe or refractory range, gut-directed hypnotherapy via the practice is generally the stronger evidence-based choice. The per-client effect size is larger and the personalization addresses the specific presentation. For clients with mild-to-moderate IBS who prefer digital-first care or who have meaningful budget constraints, Mahana is a reasonable first-line option that may be enough on its own and at minimum provides a structured trial of psychological care before any step-up. For more on the comorbidity context that often shapes this decision, see the anxiety and IBS overlap guide and the related stress-driven IBS context.

Honest framing. This is not a competition. Mahana is not trying to replace gut-directed hypnotherapy and gut-directed hypnotherapy is not trying to replace Mahana. They are different tools with different best-fit populations, different cost structures, and different trade-offs. The wrong move is forcing a comparison that frames one as always-better. The right move is matching the tool to the client.

When Mahana is a good fit

Six client profiles where Mahana is a defensible first move and where the structured digital format is likely to deliver meaningful benefit. If you fit most of these and Mahana is accessible to you (insurance, employer, affordable direct pay), it is a reasonable place to start.

Mild-to-moderate IBS without severe comorbidity. The presentation that the program is built around. Confirmed diagnosis from your GP or GI specialist, symptoms that meaningfully affect quality of life but are not producing severe functional impairment, no untreated comorbid severe anxiety or depression complicating the picture. This is the population that the Mahana trial evidence most directly applies to.

Self-motivated client comfortable with 90 days of daily app use. The structure depends on engagement. If you have a pattern of starting structured programs and finishing them, you are a good fit. If you have a pattern of downloading self-help apps and abandoning them in week two, the Mahana structure will probably go the same way and a different format may serve you better.

Cost or access barrier to in-person individual care. In-person CBT-for-IBS or gut-directed hypnotherapy is often the higher-evidence option, but if the cost is genuinely out of reach right now, Mahana is a real alternative that delivers a structured program at a fraction of the cost. This is a defensible sequencing rather than a compromise. A structured digital trial with the option to step up to in-person work later is a reasonable plan.

Preference for privacy and digital-first care. Some clients are more comfortable doing the psychological layer alone with an app than they are with a live practitioner, especially around gut symptoms that they find embarrassing to discuss. Mahana removes the interpersonal dimension entirely. For clients where that dimension is itself a barrier to engagement, the app format may produce more actual practice than a weekly in-person session would.

Step-up readiness. Clients who would consider in-person care if the app does not produce sufficient improvement at 90 days. The healthiest framing of Mahana is as a structured first trial, not a final answer. Going in with the explicit plan to evaluate at day 90 and step up to in-person work if the app has not produced meaningful change is a sensible sequencing pattern.

Concurrent gastroenterology and dietary care. Patients already working with their GI specialist and a registered dietitian who want to add the psychological layer. Mahana is designed to slot into a multi-modal IBS care plan rather than replace any of the other layers. If your medical and dietary care is already in motion, Mahana adds the psychological piece in a structured way.

When Mahana is not a good fit

Equally honest about the other direction. Some presentations are not Mahana presentations, and pretending otherwise leaves people stuck in a 90-day program that was never going to produce the change they needed. Six contraindication scenarios where the right move is something other than starting the app.

Severe IBS with significant functional impairment. Patients whose symptoms are producing major disruption to work, relationships, or daily functioning need the higher-evidence individual care from the start. In-person individual CBT-for-IBS or gut-directed hypnotherapy is more likely to produce meaningful change in this severity range. The app format is built for mild-to-moderate cases and the effect size in severe presentations is typically smaller.

Active comorbid severe anxiety, depression, or trauma. The Mahana program does not adapt to individual circumstances, and these comorbid presentations need primary mental health care from a registered psychologist or psychiatrist, not a CBT-for-IBS app running alone. If the psychological picture is dominated by a comorbid condition rather than IBS, that condition should usually drive the care plan, with IBS-specific work running alongside or deferred until the primary condition is stabilized. Per the scope-of-practice frame I work to as a Registered Clinical Hypnotherapist, hypnotherapy is also not the right primary tool for these presentations; they need their own specialty care.

Treatment-refractory IBS that has not responded to dietary management or prior psychological interventions. If you have already tried structured low-FODMAP without enough benefit, or you have done a course of in-person CBT-for-IBS or other psychological work and not landed where you needed to land, the digital-therapeutic version is unlikely to outperform the in-person version that has already underdelivered. Refractory presentations usually need experienced individual care, often gut-directed hypnotherapy via an experienced practitioner, sometimes in combination with subtype-specific medication.

Inability to maintain 90 days of consistent daily app use. Partial use produces partial benefit. The 90-day structure is not optional architecture; it is the program. If you know yourself well enough to know that you are unlikely to stick with daily app use for three months, a different format is probably more honest. Eight to twelve weekly in-person sessions is a different commitment shape and fits some people better than the daily-app structure. A full Manchester Protocol course of 8 to 12 sessions is similar total time but distributed differently.

Active eating disorder presenting with GI symptoms. This is a specific contraindication that often gets missed. When restrictive eating, binge-purge cycles, or other eating disorder behaviours are driving GI symptoms, the primary work is eating disorder specialty care, not IBS-specific psychological work. Running a CBT-for-IBS program over an active eating disorder can reinforce food-avoidance patterns rather than help. The right move is referral to a clinician who specializes in eating disorders.

Pre-diagnostic GI symptoms not yet evaluated medically. This one is hard rule. Medical workup must come before any psychological intervention for GI symptoms. Alarm features (rectal bleeding, unexplained weight loss, anaemia, family history of GI cancer, onset over age 50) need to be ruled out by a physician or specialist. As an RCH I do not diagnose IBS, and the same logic applies to a digital therapeutic. Running a CBT-for-IBS program over undiagnosed GI symptoms means treating something that may not be IBS at all. Get the medical workup first.

Frequently asked questions

If you have read this far, you have done more diligence than most patients choosing between digital therapeutic and in-person care. The practical next step depends on what you found. If your picture matches the good-fit profile and Mahana is accessible, starting the 90-day program with a clear evaluation point at the end is a reasonable plan. If your picture sits in the contraindication list, a different pathway is more honest. If you are not sure which side you fall on, that is exactly what the free consultation is for. A related read is the Reveri app review for the general self-hypnosis app context which sits in the same app-comparison cluster. When you are ready to talk through the specifics with Danny M., RCH, you can start the intake process.